Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions  

作　　者：Wei-Zhong Cheng Meng-Su Zeng Fu-Hua Yan Shen- Xiang Rao Ji-Zhang Shen Cai-Zhong Chen Shu-Jie Zhang Wei-Bin Shi 

机构地区：[1]Department of Radiology,Zhongshan Hospital,Fudan University and Department of Medical Imaging,Shanghai Medical School,Fudan University,Shanghai 200032,China

出　　处：《World Journal of Gastroenterology》2007年第36期4891-4896,共6页世界胃肠病学杂志（英文版）

摘　　要：AIM: To evaluate the efficacy of ferucarbotran-enhanced MR imaging in the detection of focal hepatic lesions compared to plain and Gd-DTPA-enhanced MR imaging. METHODS: Fifty-nine patients with suspected focal hepatic lesions were admitted to the study. Plain MR imaging (FSE T2WI with fat suppression and GRE T1WI sequences) and Gd-DTPA dynamic enhanced MR of the liver were initially performed followed by ferucarbotran- enhanced MR imaging 48 h later (including GRE T1WI, FSE T2WI with fat suppression, and GRE T2*WI sequences). Images were reviewed independently by three observers. Results were correlated with surgery and pathologic examination or reference examination, and sensitivity was statistically calculated for the different MR imaging sequences. RESULTS: Among all confirmed lesions (n = 133), ferucarbotran-enhanced MR imaging revealed 130 lesions on FSE T2WI with fat suppression, 115 lesions on dynamic T1WI GRE, and 127 lesions on GRE T2*WI. Pre-contrast MR imaging revealed only 84 lesions on GRE T1WI and 106 lesions on FSE T2WI with fat suppression, while Gd-DTPA dynamic enhanced GRE T1WI revealed 123 lesions. For 44 micro-lesions (< 1.0 cm) in all patients the detection rates were as follows: ferucarbotran-enhanced FSE T2WI with fat suppression, 93.2% (41/44); ferucarbotran-enhanced GRE T2*WI, 88.6% (39/44); Gd-DTPA dynamic-enhanced GRE T1WI, 79.5% (35/44); pre-contrast FSE T2WI with fat suppression, 54.5% (24/44); and pre-contrast GRE T1WI, 34.1% (15/44). In detecting micro-lesions, statistically significant difference was found for Ferucarbotran- enhanced FSE T2WI with fat suppression and GRE T2*WI sequences compared to the other sequences (P < 0.05).CONCLUSION: Ferucarbotran-enhanced FSE T2WI with fat suppression and GRE T2*WI sequences are superior in detecting micro-lesions (< 1 cm) in comparison with plain and Gd-DTPA dynamic-enhanced MR imaging.AIM： To evaluate the efficacy of ferucarbotran-enhanced MR imaging in the detection of focal hepatic lesions compared to plain and Gd-DTPA-enhanced MR imaging. METHODS： Fifty-nine patients with suspected focal hepatic lesions were admitted to the study. Plain MR imaging （FSE T2WI with fat suppression and GRE T1WI sequences） and Gd-DTPA dynamic enhanced MR of the liver were initially performed followed by ferucarbotran- enhanced MR imaging 48 h later （including GRE T1WI, FSE T2WI with fat suppression, and GRE T2＊WI sequences）. Images were reviewed independently by three observers. Results were correlated with surgery and pathologic examination or reference examination, and sensitivity was statistically calculated for the different MR imaging sequences. RESULTS： Among all confirmed lesions （n = 133）, ferucarbotran-enhanced MR imaging revealed 130 lesions on FSE T2WI with fat suppression, 115 lesions on dynamic T1WI GRE, and 127 lesions on GRE T2＊WI. Pre-contrast MR imaging revealed only 84 lesions on GRE T1WI and 106 lesions on FSE T2WI with fat suppression, while Gd-DTPA dynamic enhanced GRE T1WI revealed 123 lesions. For 44 micro-lesions （〈 1.0 cm） in all patients the detection rates were as follows： ferucarbotran-enhanced FSE T2WI with fat suppression, 93.2% （41/44）; ferucarbotran-enhanced GRE T2＊WI, 88.6% （39/44）; Gd-DTPA dynamic-enhanced GRE T1WI, 79.5% （35/44）; pre-contrast FSE T2WI with fat suppression, 54.5% （24/44）; and pre-contrast GRE T1WI, 34.1% （15/44）. In detecting micro-lesions, statistically significant difference was found for Ferucarbotran- enhanced FSE T2WI with fat suppression and GRE T2＊WI sequences compared to the other sequences （P 〈 0.05）.CONCLUSION： Ferucarbotran-enhanced FSE T2WI with fat suppression and GRE T2＊WI sequences are superior in detecting micro-lesions （〈 1 cm） in comparison with plain and Gd-DTPA dynamic-enhanced MR imaging.

关 键 词：Liver disease Contrast media Superpara- magnetic iron oxide Magnetic resonance imaging 

分 类 号：R575[医药卫生—消化系统]